Early treatment of multiple sclerosis to prevent neurologic damage

MS Comprehensive Care Center, Stony Brook University Medical Center, Stony Brook, NY 11794, USA.
Neurology (Impact Factor: 8.3). 12/2008; 71(24 Suppl 3):S3-7. DOI: 10.1212/WNL.0b013e31818f3d6f
Source: PubMed

ABSTRACT Multiple sclerosis (MS) involves ongoing accumulating CNS damage. Precisely which environmental factors trigger onset and progression of the disease are not known. However, clinical trials indicate benefits from early use of disease-modifying therapies (DMTs). All the completed clinically isolated syndrome trials (CHAMPS, ETOMS, BENEFIT, PRECISE) reported significant suppression of subsequent relapse and MRI lesion formation from use of DMT at the first relapse. This article reviews data on early treatment. Such an approach requires the ability to recognize clinically isolated syndrome features that indicate a diagnosis of MS.

  • [Show abstract] [Hide abstract]
    ABSTRACT: •We present a case of a young man who developed symptoms related to partial myelitis.•Interferon worsened his pre-existing psoriasis which improved with dimethyl fumarate.•Attention is drawn to the immunology underlying psoriasis and multiple sclerosis.•We advocate for individualized treatment approaches for patients with MS.•Dimethyl fumarate may be a treatment option for psoriasis.
    Journal of the Neurological Sciences 05/2014; 343(1-2). DOI:10.1016/j.jns.2014.05.031 · 2.26 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Fingolimod demonstrated superior efficacy compared with interferon β-1a intramuscular in relapsing multiple sclerosis. The impact of treatment history on fingolimod efficacy is unknown. Objectives This post-hoc analysis of phase 3 TRANSFORMS data compared the efficacy and safety of fingolimod and interferon β-1a intramuscular among patient subgroups defined by prior treatment history. Methods Annualized relapse rate and safety of once-daily oral fingolimod 0.5 mg, 1.25 mg, or once-weekly interferon β-1a 30 μg intramuscular for 12 months were analyzed in 1292 patients with relapsing multiple sclerosis according to prior disease-modifying therapy, reason for prior disease-modifying therapy discontinuation (adverse events or unsatisfactory therapeutic effect), and prior disease-modifying therapy duration. Results Compared with interferon β-1a intramuscular, fingolimod 0.5 mg significantly reduced annualized relapse rate in patients who were treatment naive, received prior interferon-β treatment, discontinued prior disease-modifying therapy for unsatisfactory therapeutic effect, or had prior disease-modifying therapy duration of ≥1 year (P≤0.05, all comparisons). Similar trends were observed in patients with prior glatiramer acetate treatment. Significant reductions were also seen with fingolimod 1.25 mg for treatment-naive and prior interferon-β–treated patients. Conclusions This analysis demonstrates superiority of fingolimod over interferon β-1a intramuscular regardless of prior (interferon-β) treatment and prior treatment efficacy and duration. identifier: NCT00340834
    01/2013; DOI:10.1016/j.msard.2013.11.006
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple sclerosis (MS) is an inflammatory, demyelinating disease that has unpredictable symptomatology and severity. Cerebellar manifestations in MS can be present at any time of the clinical course. Early cerebellar findings are a predictor of disability and disease progression. Most patients have cerebellar manifestations once they enter the progressive stages of the disease. Of the cerebellar findings, tremor is by far the most common. Copyright © 2014 Elsevier Inc. All rights reserved.
    Neurologic Clinics 10/2014; 32(4). DOI:10.1016/j.ncl.2014.08.001 · 1.61 Impact Factor